These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 3489157)

  • 41. Fluid replacement protection of rabbits challenged subcutaneous with toxic shock syndrome toxins.
    Lee PK; Deringer JR; Kreiswirth BN; Novick RP; Schlievert PM
    Infect Immun; 1991 Mar; 59(3):879-84. PubMed ID: 1997438
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Toxic shock syndrome: characterization of human immune responses to TSST-1 and evidence for sensitivity thresholds.
    Kimber I; Nookala S; Davis CC; Gerberick GF; Tucker H; Foertsch LM; Dearman RJ; Parsonnet J; Goering RV; Modern P; Donnellen M; Morel J; Kotb M
    Toxicol Sci; 2013 Jul; 134(1):49-63. PubMed ID: 23640863
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A mutation at histidine residue 135 of toxic shock syndrome toxin yields an immunogenic protein with minimal toxicity.
    Bonventre PF; Heeg H; Edwards CK; Cullen CM
    Infect Immun; 1995 Feb; 63(2):509-15. PubMed ID: 7822015
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of chemical modification of histidine and tyrosine residues in toxic shock syndrome toxin 1 on the serologic and mitogenic activities of the toxin.
    Kokan-Moore NP; Bergdoll MS
    Infect Immun; 1989 Jul; 57(7):1901-5. PubMed ID: 2499540
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The superantigen toxic shock syndrome toxin-1 induces CD40 ligand expression and modulates IgE isotype switching.
    Jabara HH; Geha RS
    Int Immunol; 1996 Oct; 8(10):1503-10. PubMed ID: 8921429
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Induction of nitric oxide synthase activity by toxic shock syndrome toxin 1 in a macrophage-monocyte cell line.
    Zembowicz A; Vane JR
    Proc Natl Acad Sci U S A; 1992 Mar; 89(6):2051-5. PubMed ID: 1372433
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Toxic shock syndrome toxin 1 binds to major histocompatibility complex class II molecules.
    Scholl P; Diez A; Mourad W; Parsonnet J; Geha RS; Chatila T
    Proc Natl Acad Sci U S A; 1989 Jun; 86(11):4210-4. PubMed ID: 2542966
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Macrophage-dependent stimulation of T cell-depleted spleen cells by Clostridium difficile toxin A and calcium ionophore.
    Miller PD; Pothoulakis C; Baeker TR; LaMont JT; Rothstein TL
    Cell Immunol; 1990 Mar; 126(1):155-63. PubMed ID: 2105851
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Contribution of toxic shock syndrome toxin-1 to systemic inflammation investigated by a mouse model of cervicovaginal infection with Staphylococcus aureus.
    Asano K; Narita K; Hirose S; Nakane A
    Med Microbiol Immunol; 2018 Nov; 207(5-6):297-306. PubMed ID: 29980843
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Activation of human vascular endothelial cells by IFN-gamma: acquisition of HLA class II expression, TSST-1-binding activity and accessory activity in T cell activation by the toxin.
    Araake M; Uchiyama T; Imanishi K; Yan XJ
    Int Arch Allergy Appl Immunol; 1991; 96(1):55-61. PubMed ID: 1752697
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Production of tumor necrosis factor by human monocytes in response to toxic-shock-syndrome toxin-1.
    Parsonnet J; Gillis ZA
    J Infect Dis; 1988 Nov; 158(5):1026-33. PubMed ID: 3263447
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Binding of toxic shock syndrome toxin-1 to murine major histocompatibility complex class II molecules.
    Scholl PR; Sekaly RP; Diez A; Glimcher LH; Geha RS
    Eur J Immunol; 1990 Sep; 20(9):1911-6. PubMed ID: 2209697
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Staphylococcus aureus-superantigen decreases FKBP51 mRNA expression and cell-response to suppressive efficacy of a glucocorticoid in human peripheral blood mononuclear cells: possible implication of mitogen-activated protein kinase pathways.
    Fukushima H; Hirano T; Oka K
    Eur J Pharmacol; 2007 Sep; 570(1-3):222-8. PubMed ID: 17610867
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Induction of selective anergy by toxic shock syndrome toxin-1 in CD8+ T cells.
    Zhao YX; Holmdahl R; Tarkowski A
    Immunology; 1997 Oct; 92(2):188-93. PubMed ID: 9415025
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Study of the biological activities of toxic shock syndrome toxin-1 (TSST-1). III. Analysis of TSST-1-induced suppression of the primary antibody response].
    XJ Y; Uchiyama T; Kawachi A; Yoshioka M; Fujikawa H; Igarashi H
    Kansenshogaku Zasshi; 1988 May; 62(5):483-9. PubMed ID: 2971093
    [No Abstract]   [Full Text] [Related]  

  • 56. The toxic shock syndrome toxin-1 induces anergy in human T cells in vivo.
    Mahlknecht U; Herter M; Hoffmann MK; Niethammer D; Dannecker GE
    Hum Immunol; 1996 Jan; 45(1):42-5. PubMed ID: 8655359
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vaccination with non-toxic mutant toxic shock syndrome toxin-1 induces IL-17-dependent protection against Staphylococcus aureus infection.
    Narita K; Hu DL; Asano K; Nakane A
    Pathog Dis; 2015 Jun; 73(4):. PubMed ID: 25857736
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mutants of staphylococcal toxic shock syndrome toxin 1: mitogenicity and recognition by a neutralizing monoclonal antibody.
    Blanco L; Choi EM; Connolly K; Thompson MR; Bonventre PF
    Infect Immun; 1990 Sep; 58(9):3020-8. PubMed ID: 1696937
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Induction of human interleukin-1 by a product of Staphylococcus aureus associated with toxic shock syndrome.
    Ikejima T; Dinarello CA; Gill DM; Wolff SM
    J Clin Invest; 1984 May; 73(5):1312-20. PubMed ID: 6609169
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bacterial superantigen TSST-1 attenuates suppressive efficacy of glucocorticoids and calcineurin inhibitors against blastogenesis of peripheral blood mononuclear cells from patients with chronic renal failure on hemodialysis treatment.
    Konno O; Hirano T; Katsuyama K; Oka K; Matsuno N; Nagao T
    Transpl Immunol; 2007 Apr; 17(3):187-92. PubMed ID: 17331845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.